Priorities & Impact

Fiscal Year 2026

Investment Priorities for America's Biodefense

For Fiscal Year 2026, the Alliance has requested sustained, increased investment across the core programs that keep the nation's biodefense pipeline ready to respond.

$1.4B BARDA Advanced Research & Development
$1B Project BioShield Special Reserve Fund
$1.588B Strategic National Stockpile
$410M Pandemic Influenza Preparedness
"The government cannot do this alone. Consistent funding and robust public-private collaboration will safeguard public health, reinforce national resilience, and ensure the availability of critical MCMs."

Alliance for Biosecurity Priorities

Advocate

For sustained, bipartisan federal investment in the programs that strengthen America's biodefense: BARDA, ASPR, Project BioShield, Pandemic Influenza, the SNS, and more.

Enhance

Public-private partnerships that accelerate innovation, streamline procurement, and close readiness gaps across the CBRN threat landscape.

Support

The development and stockpiling of next-generation countermeasures — from antibacterials and antivirals to urgently needed antifungal agents.

Promote

A coordinated, forward-looking national biodefense strategy aligned with a unified, whole-of-government framework.

Engage

With Congress, the Administration, and federal agencies to shape a forward-looking national biodefense strategy.

Educate

Policymakers, the press, and the public on the importance of sustained preparedness and domestic MCM development.

Alliance Resources

Membership

Alliance for Biosecurity Membership Overview

An overview of the Alliance's mission, priorities, and membership benefits for prospective member companies.

View PDF →

Policy Priorities

Alliance for Biosecurity Policy Priorities

The Alliance's core legislative and regulatory priorities for strengthening national biodefense.

View PDF →

Appropriations

Fiscal Year 2026 Federal Appropriations Requests

The Alliance's funding recommendations to Congress for FY2026 medical countermeasure programs.

View PDF →

Explainer

What is PAHPA?

A primer on the Pandemic and All-Hazards Preparedness Act and why it matters for national security.

View PDF →

RFI Response

Response to Reps. Hudson and Eshoo PAHPA RFI

The Alliance's formal response to the House PAHPA reauthorization request for information.

View PDF →

RFI Response

Response to Senate HELP Committee PAHPA RFI

The Alliance's formal response to the Senate HELP Committee's PAHPA reauthorization request.

View PDF →

Our Accomplishments

January 1, 2014

Advocated to preserve the BioShield Special Reserve Fund (SRF) – critical source of funding for MCM development and procurement – and successfully advocated against at least 3 proposed Congressional “raids” (up to $2 billion) of the SRF.

January 1, 2014

January 1, 2015

Successfully advocated for five-year reauthorization of BARDA and SRF in the Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA).

January 1, 2015

January 1, 2015

Served as trusted resource for Congressional staff working to better integrate FDA into the MCM development process; secured strong legislative changes in PAHPRA.

January 1, 2015

January 1, 2015

Constructively engaged with FDA on critical policy/regulatory issues related to development of MCMs, including animal models. During 2012, the Alliance was invited by FDA to (i) participate in a “hot topics” educational briefing for FDA reviewers and other professionals, and (ii) provide perspectives on GLP issues when conducting animal model studies in BSL-3 and BSL-4 Labs.

January 1, 2015

January 1, 2015

Convened an informal coalition of stakeholders (including public health and national defense organizations) committed to the long term success of the US government’s biodefense and public health preparedness enterprise to strengthen education and outreach efforts.

January 1, 2015